358 related articles for article (PubMed ID: 27591097)
1. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
[TBL] [Abstract][Full Text] [Related]
3. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
[TBL] [Abstract][Full Text] [Related]
4. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
[TBL] [Abstract][Full Text] [Related]
5. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
6. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
Kerr KM; Tsao MS; Nicholson AG; Yatabe Y; Wistuba II; Hirsch FR;
J Thorac Oncol; 2015 Jul; 10(7):985-9. PubMed ID: 26134220
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
[TBL] [Abstract][Full Text] [Related]
9. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
[TBL] [Abstract][Full Text] [Related]
10. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
Coppock JD; Volaric AK; Mills AM; Gru AA
Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
Sacher AG; Gandhi L
JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
[TBL] [Abstract][Full Text] [Related]
12. [Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].
Hofman V; Ilie M; Long E; Butori C; Lassalle S; Washetine K; Lalve S; Marquette CH; Soria JC; Hofman P
Bull Cancer; 2016 Apr; 103(4):368-80. PubMed ID: 26920041
[TBL] [Abstract][Full Text] [Related]
13. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
Phillips T; Simmons P; Inzunza HD; Cogswell J; Novotny J; Taylor C; Zhang X
Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):541-9. PubMed ID: 26317305
[TBL] [Abstract][Full Text] [Related]
14. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
[TBL] [Abstract][Full Text] [Related]
15. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
Kerr KM; Nicolson MC
Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
[TBL] [Abstract][Full Text] [Related]
16. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
[TBL] [Abstract][Full Text] [Related]
19. Comparison of
Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
[TBL] [Abstract][Full Text] [Related]
20. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
Sheng J; Fang W; Yu J; Chen N; Zhan J; Ma Y; Yang Y; Huang Y; Zhao H; Zhang L
Sci Rep; 2016 Jan; 6():20090. PubMed ID: 26822379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
